文献速递淋巴瘤造血干细胞移植与细胞治疗

高危经典霍奇金淋巴瘤接受自体移植患者的预后因素评估

Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.
PubMed 文献 · Blood Adv · 2024-01-01

ECLIPSE 是一项多中心回顾性队列研究,纳入 15 家美国医疗中心 2005 年 1 月 1 日及以后诊断的 478 例原发治疗失败(PTF)经典霍奇金淋巴瘤(cHL)患者,评估自体造血细胞移植(auto-HCT)后的预后因素。移植后 6 个月和 1 年非复发死亡率累积发生率分别为 0.9% 和 1.1%,中位无进展生存期(PFS)和总生存期(OS)分别为 4.33 年和 10.09 年;移植时未达完全缓解(CR)与较差的 PFS 和 OS 相关,高龄和 2011 年前诊断与较差的 OS 相关。

要点

  • 478 例 PTF-cHL 患者中,原发进展 217 例(45%)、部分缓解/疾病稳定 86 例(18%)、早期复发 175 例(37%)。
  • auto-HCT 后 6 个月和 1 年非复发死亡率累积发生率分别为 0.9% 和 1.1%。
  • auto-HCT 后中位 PFS 为 4.33 年,中位 OS 为 10.09 年。

核心结论

  • 本研究展示了 auto-HCT 即使在传统认为化疗难治的高危患者中仍具有安全性和长期疗效,并将为正在进行的移植对比不移植试验提供基准。

研究设计与样本

  • ECLIPSE 是一项多中心回顾性队列研究,纳入 15 家美国医疗中心 2005 年 1 月 1 日及以后诊断的 478 例年龄≥15 岁的 PTF-cHL 患者。
  • PTF 定义为以下之一:前线化疗期间或完成后 6 周内经影像学证实的进展性疾病(原发进展 PP);前线治疗完成后影像学示部分缓解(PR)或疾病稳定(SD);前线治疗完成后 12 个月内经影像学(并经活检证实)的疾病进展,且此前已记录完全缓解(CR;早期复发 ER)。

主要发现

  • 478 例患者中,PP 217 例(45%),PR/SD 86 例(18%),ER 175 例(37%)。
  • auto-HCT 后 6 个月和 1 年非复发死亡率累积发生率分别为 0.9% 和 1.1%。
  • auto-HCT 后中位 PFS 为 4.33 年,中位 OS 为 10.09 年。
  • auto-HCT 时未达 CR 与较差的 PFS 和 OS 相关。
  • 高龄和 2011 年前诊断与较差的 OS 相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are limited data assessing the risk scores for primary treatment failure (PTF) in patients with classical Hodgkin lymphoma (cHL; PTF-cHL) undergoing autologous hematopoietic cell transplantation (auto-HCT). ECLIPSE (Evaluation of Classical Hodgkin Lymphoma patients wIth Primary treatment failure and analySis of outcomEs) is a multicenter retrospective cohort of patients with PTF-cHL (aged ≥15 years) diagnosed on or after 1 January 2005, at 15 US medical centers. PTF was defined as 1 of the following patterns of failure: (1) progressive disease by imaging during or within 6 weeks of completion of frontline chemotherapy (primary progression [PP]); (2) partial response (PR) or stable disease (SD) by imaging after completion of frontline treatment (PR/SD); (3) progression of disease by imaging (and confirmed by biopsy) within 12 months of frontline therapy completion after prior documentation of complete response (CR; early relapse [ER]). A total of 478 patients were included in the analysis. Among these, 217 (45%) were PP, 86 (18%) were PR/SD, and 175 (37%) were ER. The 6-month and 1-year cumulative incidence of nonrelapse mortality after auto-HCT were 0.9% and 1.1%, respectively. The median progression-free survival (PFS) and overall survival (OS) after auto-HCT were 4.33 and 10.09 years, respectively. Although those not in CR at the time of auto-HCT were associated with inferior PFS and OS, advanced age and diagnosis before 2011 were associated with inferior OS. This study showcases the safety and long-term efficacy of auto-HCT, even in patients with high-risk disease who are traditionally considered chemotherapy refractory, and will serve as a benchmark for the ongoing transplant vs no transplant trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Epperla N, Huang Y, Cashen AF, et al. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Adv. 2024. PMID: 39213424. doi:10.1182/bloodadvances.2024013743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。